focus -WSS

focus

author：Wikipedia 2025-09-27 12:55:41 - browse：9936

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： American taxpayers paid $1.8 trillion in health care costs in 2022

WSS

Life science postdocs should get big pay hike, NIH panel says

Hospital chaplains balance Covid safety with patients’ spiritual needs

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Boston Scientific acquires urology company Axonics for $3.7 billion

Physician assistants need a new name. Here's what it should be

American taxpayers paid $1.8 trillion in health care costs in 2022

leisure time

focus

hotspot

Hollywood unions extend contract negotiations for actors

FDA early review: GLP

New air purifier tech could be key to improving indoor air quality

Physician assistants need a new name. Here's what it should be

The cancer drug shortage isn’t new — and neither are the solutions

Merck to acquire Harpoon Therapeutics for $680 million

Anesthesiologist group: stop taking Ozempic before surgery

Life science postdocs should get big pay hike, NIH panel says

New air purifier tech could be key to improving indoor air quality

Study suggests new cause of Down syndrome: cells linked to aging

entertainment

JPM pitch from hospitals? Revenue streams outside of patient care

Life science postdocs should get big pay hike, NIH panel says

A preacher's new calling: Diversifying neuroscience research

Merck to acquire Harpoon Therapeutics for $680 million

Physician assistants need a new name. Here's what it should be

Medicare Advantage overpayments discussion gets experts fired up

Wikipedia

leisure time

leisure time

leisure time